Stocks:
5,168
ETFs:
2,288
Exchanges:
11
Market Cap:
$63.92T
24h Vol:
$4.36B
Dominance:
MSFT:4.92%
Stocklytics Platform
Instrument logo  VINC
Vincerx, Inc.
VINC
51 / 100
Penny Stock
$1.000.00%$0.00

Performance History

Stocklytics logo
Key Stats
Open$1.01
Prev. Close$1.00
EPS-1.89
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap21594406.00
PE Ratio-
LOWHIGH
Day Range0.95
1.01
52 Week Range0.61
9.37
Ratios
P/B Ratio1.89
Revenue-
Operating M. %0.00%
Earnings$0.00
Earnings Growth %38.57%
EBITDA Margin %-
ROE %-136.38%
EPS-1.89

Score Breakdown

51vs 55. Market Avg.

All Score 51 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

VINCMARKET
Value5440
Quality2940
Ownership2817
Growth5745
Dividends-38
check_circle

Vincerx, Inc.'s Price discount from 1 year high of 87.62% is great compared to market average of 18.05%. This indicates VINC could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$751.62
24H (%)arrow_drop_down1.04%
24H ($)-$7.97
MARKET CAP$724.46B
PRICE$438.91
24H (%)arrow_drop_down0.63%
24H ($)-$2.81
MARKET CAP$414.91B
PRICE$147.57
24H (%)arrow_drop_down0.81%
24H ($)-$1.21
MARKET CAP$361.94B
PRICE$126.33
24H (%)arrow_drop_up0.14%
24H ($)$0.18
MARKET CAP$321.01B

About Vincerx, Inc. (VINC)

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Ahmed M. Hamdy M.D.
Headquarters
Palo Alto
Employees
41
Exchange
NASDAQ
add Vincerx, Inc. to watchlist

Keep an eye on Vincerx, Inc.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Vincerx, Inc.'s (VINC) price per share?

The current price per share for Vincerx, Inc. (VINC) is $1. The stock has seen a price change of $0 recently, indicating a 0% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Vincerx, Inc. (VINC)?

For Vincerx, Inc. (VINC), the 52-week high is $9.37, which is 837.2% from the current price. The 52-week low is $0.61, the current price is 63.93% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Vincerx, Inc. (VINC) a growth stock?

Vincerx, Inc. (VINC) has shown an average price growth of -50.46% over the past three years. It has received a score of 5 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Vincerx, Inc. as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Vincerx, Inc. (VINC) stock price performance year to date (YTD)?

As of the latest data, Vincerx, Inc. (VINC) has a year-to-date price change of -15.4%. Over the past month, the stock has experienced a price change of -85.03%. Over the last three months, the change has been -23.61%. Over the past six months, the figure is 3.09%.

help
Is Vincerx, Inc. (VINC) a profitable company?

Vincerx, Inc. (VINC) has a net income of -$40.16M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$42.61M. Furthermore, the EBITDA is -$52.44M.

help
What is the market capitalization of Vincerx, Inc. (VINC)?

Vincerx, Inc. (VINC) has a market capitalization of $21.59M. The average daily trading volume is 2.72M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.